Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9994892 | 0.92 | GPR119 (0.44) | GPR119 | |
| SCHEMBL485093 | 0.88 | GPR119 (0.53) | GPR119USP2SMN1; SMN2HPGD | |
| SCHEMBL14661920 | 0.86 | EPHX2 (0.38) | GPR119EPHX2USP2SMN1; SMN2HPGD | |
| SCHEMBL14662698 | 0.84 | HPGD (0.39) | GPR119EPHX2USP2SMN1; SMN2NAMPT | |
| SCHEMBL31565546 | 0.83 | GPR119 (0.46) | GPR119 | |
| SCHEMBL25234342 | 0.82 | GPR119 (0.49) | GPR119EPHX2USP2SMN1; SMN2NAMPT | |
| SCHEMBL1474868 | 0.82 | USP2 (0.49) | GPR119EPHX2USP2SMN1; SMN2NAMPT | |
| SCHEMBL21384373 | 0.81 | GPR119 (0.40) | GPR119EPHX2HPGD | |
| SCHEMBL21401557 | 0.81 | GPR119 (0.40) | GPR119EPHX2HPGD | |
| SCHEMBL30845965 | 0.81 | GPR119 (0.40) | GPR119EPHX2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079983-A | FGFR3 inhibitor compounds | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079985-A | FGFR3 inhibitor compounds | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079984-A | FGFR3 inhibitor compounds | — | 2026-05-26 | — | — | CN | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12606533-B2 | 3-phenylpropylamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4514794-B1 | FGFR2 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12558428-B2 | Heterobifunctional compounds and their use in treating disease | HALDA THERAPEUTICS OPCO, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12539295-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | OZAKI FUMIHIRO | 2007-12-20 | — | — | US | disclosed |
| US-7265108-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265108-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265108-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| EP-1484327-B1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | EISAI R&D MAN CO LTD (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1484327-B1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | EISAI R&D MAN CO LTD (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-6995144-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20050245527-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1484327-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | Eisai Co., Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | XDH, NQO1, CYP1A1 | GPR119 2649/4885EPHX2 1557/4885USP2 3639/4885 |
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | GPR119 1443/4885EPHX2 3556/4885USP2 740/4885 |
| US-12539295-B2 | IRAK degraders and uses thereof | IRAK2, IRAK4, IRAK3 | GPR119 812/4885EPHX2 1576/4885USP2 551/4885 |
| US-12558428-B2 | Heterobifunctional compounds and their use in treating disease | BRCA1, H1-0, FOXM1 | GPR119 2252/4885EPHX2 1242/4885USP2 4440/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | GPR119 932/4885EPHX2 1830/4885USP2 684/4885 |
| US-12606533-B2 | 3-phenylpropylamine derivative | SF3A1, SF1, HTR1D | GPR119 467/4885EPHX2 2146/4885USP2 1847/4885 |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | NQO1, CBR1, NOX1 | GPR119 1520/4885EPHX2 2349/4885USP2 3522/4885 |
| US-20050245527-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | XDH, NQO1, CYP1A1 | GPR119 2649/4885EPHX2 1557/4885USP2 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.